Medivation (MDVN) Submits NDA for Enzalutamide to U.S. FDA
Get Alerts MDVN Hot Sheet
Join SI Premium – FREE
Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (TSE: 4503) announced that Medivation has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for enzalutamide (formerly MDV3100). The compound has been studied in patients with castration-resistant prostate cancer who have received docetaxel therapy.
Pursuant to the Prescription Drug User Fee Act (PDUFA), the FDA is expected to determine within 60 days whether to accept the filing for review. Medivation has requested Priority Review, a designation given to drugs that offer a significant improvement in treatment or provide treatment where no satisfactory alternative therapy exists. If a Priority Review is granted, the FDA goal for completing a review is six months.
Pursuant to the Prescription Drug User Fee Act (PDUFA), the FDA is expected to determine within 60 days whether to accept the filing for review. Medivation has requested Priority Review, a designation given to drugs that offer a significant improvement in treatment or provide treatment where no satisfactory alternative therapy exists. If a Priority Review is granted, the FDA goal for completing a review is six months.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crinetics Pharmaceuticals (CRNX) Reports paltusotine met Primary and All Secondary Endpoints
- lululemon athletica (LULU) Appoints Teri List to its Board
- Conduit Pharmaceuticals (CDT) Appoints Joanne Holland as Chief Scientific Officer
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!